Analysts’ Top Healthcare Picks: Spruce Biosciences (SPRB), Dermata Therapeutics (DRMA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spruce Biosciences (SPRB – Research Report), Dermata Therapeutics (DRMA – Research Report) and OptimizeRx (OPRX – Research Report) with bullish sentiments.

Spruce Biosciences (SPRB)

RBC Capital analyst Gregory Renza maintained a Buy rating on Spruce Biosciences yesterday and set a price target of $8.00. The company’s shares closed last Monday at $2.19.

According to TipRanks.com, Renza is a 4-star analyst with an average return of 8.7% and a 43.9% success rate. Renza covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals, Pacira Pharmaceuticals, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Spruce Biosciences is a Strong Buy with an average price target of $7.40.

See Insiders’ Hot Stocks on TipRanks >>

Dermata Therapeutics (DRMA)

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Dermata Therapeutics, with a price target of $4.00. The company’s shares closed last Monday at $1.16, close to its 52-week low of $0.98.

According to TipRanks.com, Vendetti has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -3.2% and a 32.1% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Guardion Health Sciences, and SeaStar Medical Holding.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dermata Therapeutics with a $4.00 average price target.

OptimizeRx (OPRX)

RBC Capital analyst Sean Dodge maintained a Buy rating on OptimizeRx yesterday and set a price target of $14.00. The company’s shares closed last Monday at $12.57, close to its 52-week low of $11.59.

According to TipRanks.com, Dodge ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -2.7% and a 40.6% success rate. Dodge covers the Healthcare sector, focusing on stocks such as Privia Health Group, Healthcare Services, and NextGen Healthcare.

Currently, the analyst consensus on OptimizeRx is a Strong Buy with an average price target of $19.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.